1O Furmonertinib versus gefitinib in treatment-naïve EGFR mutated non-small cell lung cancer: A randomized, double-blind, multi-center, phase III study (FURLONG)
Titel:
1O Furmonertinib versus gefitinib in treatment-naïve EGFR mutated non-small cell lung cancer: A randomized, double-blind, multi-center, phase III study (FURLONG)
Auteur:
Shi, Y-K. Chen, G. Wang, X. Liu, Y. Wu, L. Hao, Y. Liu, C. Zhu, S. Zhang, X. Li, Y. Liu, J. Cao, L. Cheng, Y. Zhao, H. Zhang, S. Zang, A. Cui, J. Feng, J. Liu, F. Gu, C.